Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...
Novo Nordisk recently made headlines petitioning FDA to stop the compounding of its blockbuster GLP-1 products so it can sell its patented semaglutide drugs exclusively. Compounding is the practice of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback